SCHEMBL7762282

SCHEMBL7762282

CC(=O)SC(CCCN1C(=O)c2ccccc2C1=O)C(=O)N(C(=O)OCc1ccccc1)[C@@](Cc1ccccc1)(C(=O)O)C(=O)[C@@H](NC(=O)OCc1ccccc1)C(C)C

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
RAB9A P51151 1/20 0.43
CTSB P07858 4/20 0.37
CTSK P43235 4/20 0.37
CTSS P25774 3/20 0.37
CTSL P07711 3/20 0.37
ELANE P08246 7/20 0.35
CAPN1 P07384 2/20 0.34
CTRC Q99895 2/20 0.34
CCR1 P32246 1/20 0.34
CASP1 P29466 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7384376 0.94 CYP3A4 (0.41) CYP3A4CYP2D6CYP2C9CYP2C19RAB9A
SCHEMBL7424322 0.89 CTSK (0.42) CYP3A4CYP2D6CYP2C9CYP2C19RAB9A
SCHEMBL7377048 0.86 CTSK (0.41) CYP3A4CYP2D6CYP2C9CYP2C19RAB9A
SCHEMBL7380606 0.84 CTSK (0.40) CYP3A4CYP2D6CYP2C9CYP2C19RAB9A
SCHEMBL7384005 0.81 CTSK (0.41) CYP3A4CYP2D6CYP2C9CYP2C19RAB9A
SCHEMBL7382469 0.79 CTSL (0.38) CTSBCTSKCTSSCTSLELANE
SCHEMBL7384528 0.79 CTSK (0.43) CYP3A4CYP2D6CYP2C9CYP2C19RAB9A
SCHEMBL7381006 0.79 CTSK (0.39) CYP3A4CYP2D6CYP2C9CYP2C19RAB9A
SCHEMBL7381556 0.77 NMBR (0.41) CTSBCTSKCASP1
SCHEMBL7425528 0.77 CTSK (0.42) CYP3A4CYP2D6CYP2C9CYP2C19RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1098662-A2 COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS WARNER-LAMBERT COMPANY (US) 2001-05-16 EP disclosed
WO-2000004892-A2 COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS WARNER-LAMBERT COMPANY (US) 2000-02-03 WO disclosed